This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

97% reduction in treatment burden at nine months after treatment with ABBV-RGX-314Data consistent with that from multiple previous studies demonstrating favorable safety and efficacy profile Well tolerated with zero cases of intraocular inflammation in a setting of no prophylactic steroids Data highlight the potential of ABBV-RGX-314 to treat both eyes in wet AMD ROCKVILLE, Md., Oct. 21, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced positive data from the Phase II fellow eye sub-study e ...

ROCKVILLE, Md., Oct. 18, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present new interim data evaluating subretinal delivery of ABBV-RGX-314 in patients with bilateral wet age-related macular degeneration (wet AMD) at the American Academy of Ophthalmology 2024 annual meeting. ABBV-RGX-314 is an investigational one-time AAV Therapeutic being developed in collaboration with AbbVie for the treatment of wet AMD, diabetic retinopathy and other additional chronic retinal condit ...

ROCKVILLE, Md., Sept. 23, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Chardan's 8th Annual Genetic Medicines Conference on Monday, September 30, 2024. Chardan's 8th Annual Genetic Medicines Conference Fireside Chat: Monday, September 30, 2024 at 8:30 a.m. ET Location: New York, NY A live webcast of the fireside chat can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approx ...

Life sciences veteran Mitchell Chan joins the company ahead of multiple catalysts across late-stage gene therapy programs Vit Vasista steps down following more than 15 years at the Company ROCKVILLE, Md., Sept. 17, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that Mitchell Chan has been appointed as Executive Vice President and Chief Financial Officer, effective today. A veteran finance executive and operating partner in the biotechnology industry, Mr. Chan has held key roles in raisin ...

- Data from pivotal dose level demonstrates long-term, sustained reductions in CSF levels of HS D2S6, a key biomarker of brain disease in MPS II - 80% of patients who received the pivotal dose discontinued intravenous enzyme replacement therapy or remained treatment-naïve - Submission of a rolling BLA using the accelerated approval pathway on track for Q3 2024 ROCKVILLE, Md., Sept. 3, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced positive results from the Phase I/II/III CAMPSIITE® trial ...

ROCKVILLE, Md., Aug. 29, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate the following upcoming investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference Fireside Chat: Thursday, September 5, 2024 at 5:35 p.m. ET Location: New York, NY Baird 2024 Global Healthcare Conference Fireside Chat: Wednesday, September 11, 2024 at 9:40 a.m. ET Location: New York, NY Live webcasts of the fireside chats at the Morgan Stanley and Baird conferences can be access ...

ROCKVILLE, Md., Aug. 8, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on Thursday, August 15, 2024. H.C. Wainwright 4th Annual Ophthalmology Virtual Conference Panel: The Evolving Therapeutic Landscape of AMD Date/Time: Thursday, August 15, 2024 at 9:00 a.m. EDT Location: Virtual A live webcast of the panel can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archiv ...

Shares of Regenxbio (RGNX) have gained 17.7% over the past four weeks to close the last trading session at $12.51, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $41.83 indicates a potential upside of 234.4%. The average comprises 12 short-term price targets ranging from a low of $28 to a high of $61, with a standard deviation of $9.47. While the lowest estimate indicates an in ...

Regenxbio (RGNX) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $1.29. This compares to loss of $1.66 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 18.60%. A quarter ago, it was expected that this biotechnology company would post a loss of $1.28 per share when it actually produced a loss of $1.38, delivering a surprise of -7.81%. Over the last four quarters, the company ha ...